Literature DB >> 2783253

High affinity dopamine binding to mouse thymocytes and Mytilus edulis (Bivalvia) hemocytes.

G B Stefano1, X H Zhao, D Bailey, M Metlay, M K Leung.   

Abstract

The present report demonstrates that both mouse thymocytes and Mytilus edulis hemocytes contain a novel type of dopamine receptor. Scatchard analysis of these data revealed a single class of high-affinity binding sites with an affinity constant (Kd) of 6.6 nM, and a binding site density (Bmax) of 141 pmol/g protein in mice and a Kd of 7.6 nM and a Bmax of 66 pmol/g protein for the hemocytes. In older Mytilus the Kd was the same; however, there was a significant decrease in the Bmax (48 pmol/g protein; P greater than 0.05). Age changes were not evident for the mouse cells. The ability of a variety of other related drugs to displace specifically bound dopamine was investigated. The catecholamines (norepinephrine greater than epinephrine) and the dopamine agonist epinine were the most potent of the ligands tested and apomorphine and butaclamol were of moderate potency. This may serve to indicate that this dopamine binding site may be very different from the known D1 and D2 sites. This particular site may represent a third type of dopaminergic receptor. Furthermore, the hemocytes of Mytilus appear to be of two major types, namely, cells with a granular cytoplasm and those whose cytoplasm is agranular. Histofluorescence studies on the hemocytes reveal that a subpopulation of the granule-containing cells appears to contain serotonin.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2783253     DOI: 10.1016/0165-5728(89)90160-4

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  9 in total

1.  Cellular immunity in an annelid (Nereis diversicolor, Polychaeta): production of melanin by a subpopulation of granulocytes.

Authors:  E Porchet-Henneré; G Vernet
Journal:  Cell Tissue Res       Date:  1992-07       Impact factor: 5.249

Review 2.  Invertebrate and vertebrate neuroimmune and autoimmunoregulatory commonalties involving opioid peptides.

Authors:  G B Stefano
Journal:  Cell Mol Neurobiol       Date:  1992-10       Impact factor: 5.046

3.  Glial localization of interleukin-1 alpha in invertebrate ganglia.

Authors:  L R Paemen; E Porchet-Hennere; M Masson; M K Leung; T K Hughes; G B Stefano
Journal:  Cell Mol Neurobiol       Date:  1992-10       Impact factor: 5.046

4.  Levels of serotonin in the hemolymph of Aplysia are modulated by light/dark cycles and sensitization training.

Authors:  J Levenson; J H Byrne; A Eskin
Journal:  J Neurosci       Date:  1999-09-15       Impact factor: 6.167

5.  Stimulatory effects of opioid neuropeptides on locomotory activity and conformational changes in invertebrate and human immunocytes: evidence for a subtype of delta receptor.

Authors:  G B Stefano; P Cadet; B Scharrer
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

6.  Interaction of immunoactive monokines (interleukin 1 and tumor necrosis factor) in the bivalve mollusc Mytilus edulis.

Authors:  T K Hughes; E M Smith; R Chin; P Cadet; J Sinisterra; M K Leung; M A Shipp; B Scharrer; G B Stefano
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

7.  Lipopolysaccharide and opioids activate distinct populations of Mytilus edulis immunocytes.

Authors:  T K Hughes; E M Smith; J A Barnett; R Charles; G B Stefano
Journal:  Cell Tissue Res       Date:  1991-05       Impact factor: 5.249

8.  Immunosuppression in the definitive and intermediate hosts of the human parasite Schistosoma mansoni by release of immunoactive neuropeptides.

Authors:  O Duvaux-Miret; G B Stefano; E M Smith; C Dissous; A Capron
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-15       Impact factor: 11.205

9.  Selective effects of human immunodeficiency virus (HIV) gp120 on invertebrate neurons.

Authors:  G B Stefano; M Sawada; E M Smith; T K Hughes
Journal:  Cell Mol Neurobiol       Date:  1993-12       Impact factor: 5.046

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.